Skip to content

Brain Works

Facebook
Twitter
LinkedIn
Ariana Gatt talks about pharma, fruit fly research, and Alzheimer’s and Parkinson’s disease.
Ariana Gatt
Ariana Gatt

In 2008 I graduated from the University of Malta with a B.Sc. in Chemistry and Biology. Then, I worked as an R&D chemist with SoleaPharma Ltd., which also allowed me to spend six months training in pharmaceutical chemistry in Spain at the mother company Gadea Pharmaceuticals. I learned a lot in this period—not only lab work skills, but also about the whole business and industry. However, after two years working in the pharma industry, I realised I still wanted to further my studies.

I had always dreamed of studying abroad and experiencing a university in another country, so I applied for Masters courses in the UK. I had realised by this point that I wanted to carry out biomedical research, with a particular interest in neuroscience. I read for an M.Sc. in molecular sciences and biomedical research at King’s College London, funded by an EU funded STEPS scholarship. The M.Sc. opened the door for a Ph.D. in the same lab, which I am currently finishing .

For my Ph.D., I am investigating the role of mitochondrial dysfunction in neurodegeneration. Mitochondria produce energy for our cells. They are especially important in brain cells, since the brain uses 20% of the body’s energy. In neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, mitochondria stop functioning properly, leading to a loss of energy in the brain. This may contribute to the eventual death of brain cells. In my project, I am modelling the loss of mitochondrial function in fruit flies (Drosophila melanogaster) to understand the early stages of neurodegeneration. Fruit flies and humans share many genes and therefore, studying the genes involved in mitochondrial dysfunction in the fly allows us to find potential early treatments to prevent irreparable damage in human neurodegenerative diseases. 

Part of my Ph.D. focuses on studying human tissue from patients who have died from these diseases. These post-mortem tissue samples are obtained from UK brain banks. I am using them to identify genes that are involved in these diseases. 

I don’t know what lies ahead in my career path. I hope it will involve answering questions regarding brain function and helping to solve the many puzzles related to neurodegenerative disease. 

Author

More to Explore

Molecular Mail: Tiny Parcels for Tracking Tumours

Tumours are not discreet. As cancer cells grow and change, they release microscopic particles into their environment. Some of these particles enter the bloodstream. They are small, abundant, and, as researchers are beginning to realise, potentially informative. A Maltese research project is testing whether extracellular vesicles can provide a less invasive source of cancer information.

The Colour of Malta

Matylda Maria Jarosz is an artist who recently exhibited Walking the Coastline, which uses materials from Malta’s natural space to depict that same wilderness. Following her experience and master’s at the University of Malta, she will be teaching courses on Contemporary Weaving and Sustainable Art later in the year. THINK’s Jonathan Firbank speaks with Jarosz about her Master of Arts project, and the journey it represents.

The Doctor’s New Partner: Artificial Intelligence in Medicine

For centuries, medicine has balanced science with experience and intuition. Two patients with the same diagnosis may receive the same treatment, yet their outcomes can differ dramatically. That has long been one of medicine’s most frustrating mysteries, and one of its biggest challenges. Today, artificial intelligence (AI) is beginning to close this gap. What was once a vision of the future is now entering clinics, laboratories, and even operating rooms, redefining how care is delivered and how doctors and patients interact.

Comments are closed for this article!